Skip to main content

Factor XIII Deficiency

An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
NCT00945906 | PHASE 3 | INTERVENTIONAL

Congenital deficiency of factor XIII is an extremely rare inherited disorder associated with potentially life-threatening bleeding. Factor XIII Concentrate is given to patients whose blood is lacking factor XIII. Factor XIII Concentrate works by assisting blood in the usual clotting process, thereby preventing bleeding. In this study, patients will be treated with FXIII Concentrate (Human) and followed closely to determine that they receive the dose of FXIII Concentrate (Human) that will best minimize the chance of bruising and bleeding. The purpose of the study is to provide FXIII Concentrate (Human) to patients until the product becomes commercially available in the United States.

Trial Information
25 Sites
61 Participants
Recruiting
18 Years to 65 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Study Site
Dothan,Alabama,United States,36301
Study Site
Oakland,California,United States,94609
Study Site
Orange,California,United States,92868
Study Site
San Francisco,California,United States,94118
Study Site
Stockton,California,United States,95204
Study Site
Fort Myers,Florida,United States,33908
Study Site
Miami,Florida,United States,33136
Study Site
St. Petersburg,Florida,United States,33701
Study Site
New Orleans,Louisiana,United States,70121
Study Site
Boston,Massachusetts,United States,02115
Study Site
Ann Arbor,Michigan,United States,48109
Study Site
Detroit,Michigan,United States,48201
Study Site
Kansas City,Missouri,United States,64108
Study Site
Las Vegas,Nevada,United States,89109
Study Site
Lebanon,New Hampshire,United States,03756
Study Site
Albany,New York,United States,12208
Study Site
New York,New York,United States,10065
Study Site
Chapel Hill,North Carolina,United States,27599
Study Site
Columbus,Ohio,United States,43205
Study Site
Hershey,Pennsylvania,United States,17033
Study Site
Sioux Falls,South Dakota,United States,57105
Study Site
Nashville,Tennessee,United States,37232
Study Site
Dallas,Texas,United States,75390
Study Site
Houston,Texas,United States,77030
Study site
Milwaukee,Wisconsin,United States,53223

Study Eligibility Criteria

Additional Studies

Additional studies can be found at ClinicalTrials.gov